Vendor comparison · 2026
Eloralintide vendors: 1 compared on COAs and price
MetabolicAlso known as LY3841136
Evidence tier
Limited published literature
8 publications over 1 year · trials not yet curated
- Vendors carrying it
- 1
- 1 with a listed price
- Vendors with checkable COAs
- 1
- 1 publish any certificate
- Lots tested
- 2
- 2 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 27 Jul 2026
- oldest 26 Jul 2026
- Laboratories named
- 1
- most often Freedom Diagnostics Testing
- Median label gap
- 9.6%
- 0% of lots within 5% of label
- Median purity
- 99.69%
- 2 of 2 lots at 99% or above
- Lowest price per mg
- $14.00
- peer median $14.00
- Publications located
- 8
- researched since 2025
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
PeptidePlugs has the most checkable Eloralintide testing in this index: 2 lots assayed by Freedom Diagnostics Testing, the newest on 27 Jul 2026. The lowest listed price is $14.00 per mg at PeptidePlugs, the same vendor, against a peer median of $14.00. 1 vendor carrying Eloralintide is compared below. 1 publish at least one certificate naming a checkable laboratory, 2 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Eloralintide
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PeptidePlugs | 84.394% | $14.00 (100%) | 2 / 2 | Freedom Diagnostics Testing | 99.7% | 9.6% |
Independent assays
No independently commissioned assay of Eloralintide is on file. All 2 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
2 of 2 lots at 99% or above; median 99.69%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 0 |
| 99–99.5% | 0 |
| ≥99.5% | 2 |
0% of lots within 5% of the labelled mass; median gap 9.6%.
| Range | lots |
|---|---|
| ≤2% | 0 |
| 2–5% | 0 |
| 5–10% | 1 |
| 10–20% | 1 |
| >20% | 0 |
1 vendors, $14.00 to $14.00; median $14.00.
| Range | vendors |
|---|---|
| $14.00 | 1 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 2 | 1 | 100% | Public lookup |
Every certificate record
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Report |
|---|---|---|---|---|---|---|---|---|
 PeptidePlugs | 105-05-RB | Freedom Diagnostics Testing | 10 mg | 10.76 mg | 7.6% | 99.5% | Vendor-published | |
| PeptidePlugs | 105-01-RB | Freedom Diagnostics Testing | 5 mg | 4.42 mg | 11.6% | 99.9% | Vendor-published |
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2025 — 1 year of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
8 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.7% across 2 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.16 pts purity across lots, mean label deviation 9.6%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
1 of 1 listing vendor publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
2 of 2 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Eloralintide?
A selective, long-acting amylin receptor agonist peptide (LY3841136) in clinical development for obesity and weight management.
Studied in published research for obesity and weight management, as an amylin receptor agonist.
Regulatory status
Eloralintide is an investigational compound in clinical development and is not an approved medicine in the United States, United Kingdom or European Union. Products listed here are labeled by their vendors for laboratory research use only.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept — Molecular metabolism (2025)
Peer-reviewed article indexed in PubMed, published in Molecular metabolism (2025).
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial — Lancet (London, England) (2025)
Peer-reviewed article indexed in PubMed, published in Lancet (London, England) (2025).
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials — Diabetes, obesity & metabolism (2026)
Peer-reviewed article indexed in PubMed, published in Diabetes, obesity & metabolism (2026).
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes — Peptides (2026)
Peer-reviewed article indexed in PubMed, published in Peptides (2026).
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs — Pharmacological research (2026)
Peer-reviewed article indexed in PubMed, published in Pharmacological research (2026).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.